“Abzena inside” product to enter Phase II clinical trial

Abzena, a life sciences group providing services and technologies enabling the development and manufacture of biopharmaceutical products, has reported that one of the ‘Abzena inside’ Composite Human Antibody products for the treatment of neurodegenerative conditions has moved to Phase II clinical trial.

Abzena use term “Abzena inside” to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies and ThioBridge Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on “Abzena inside” products.